2025年美国头痛学会指南更新:急诊成人偏头痛急性发作的胃肠外药物治疗
该指南由美国头痛学会对2016版进行更新,采用系统评价与Meta分析,检索截至2025年2月10日,纳入26项新RCT(12项I级、9项II级、4项III级),评估20种注射治疗。丙氯拉嗪静脉注射、右酮洛芬静脉注射、舒马曲普坦皮下注射和枕大神经阻滞被判定为高度可能有效;氯丙嗪静脉注射、甲氧氯普胺静脉注射、依替奈珠单抗静脉注射、酮咯酸静脉注射和眶上神经阻滞为可能有效;氢吗啡酮静脉注射、丙泊酚静脉注射和对乙酰氨基酚静脉注射为可能无效。最终推荐丙氯拉嗪静脉注射和枕大神经阻滞必须提供(A级),氢吗啡酮静脉注射必须不提供(A级)。
要点
- 无禁忌的急诊偏头痛成人,丙氯拉嗪静脉注射和枕大神经阻滞必须提供(A级-必须提供)。
- 氢吗啡酮静脉注射必须不提供(A级-必须不提供),对乙酰氨基酚静脉注射可不提供(C级-不应提供)。
- 应提供(B级)的治疗包括右酮洛芬静脉注射、酮咯酸静脉注射、甲氧氯普胺静脉注射、舒马曲普坦皮下注射和眶上神经阻滞。
- 可提供(C级)的治疗包括氯丙嗪静脉注射、地塞米松静脉注射和丙戊酸静脉注射。
- 依替奈珠单抗仅对符合临床试验人群者应提供(B级),对急诊特定人群为U级-无推荐。
适用人群与场景
- 诊断为偏头痛、在急诊接受静脉、肌内、皮下或神经阻滞(含蝶腭神经节阻滞)干预的成人。
- 纳入标准为随机对照试验中的成人偏头痛患者;排除人群原文未具体列出。
诊断标准与关键阈值
- 证据分级采用美国神经病学学会(AAN)标准:I级为低偏倚风险,II级、III级依次增高。
- 疗效分类:高度可能有效、可能有效、可能无效。
- 推荐等级:A级-必须提供、A级-必须不提供、B级-应提供、C级-可提供、C级-不应提供、U级-无推荐。
处置流程与药物剂量
- 丙氯拉嗪静脉注射:对无禁忌的急诊偏头痛成人必须提供(A级-必须提供)。
- 枕大神经阻滞:对无禁忌的急诊偏头痛成人必须提供(A级-必须提供)。
- 右酮洛芬静脉注射、酮咯酸静脉注射、甲氧氯普胺静脉注射、舒马曲普坦皮下注射、眶上神经阻滞:适当时应提供(B级-应提供)。
- 氯丙嗪静脉注射、地塞米松静脉注射、丙戊酸静脉注射:可提供(C级-可提供)。
- 依替奈珠单抗静脉注射:仅对符合临床试验人群者应提供(B级);对急诊特定人群为U级-无推荐。
- 氢吗啡酮静脉注射:必须不提供(A级-必须不提供);对乙酰氨基酚静脉注射:不应提供(C级-不应提供)。
- 咖啡因、格拉司琼、布洛芬、氯胺酮、利多卡因、生理盐水、丙泊酚和蝶腭神经节阻滞:目前均为U级-无推荐,需更多证据。
研究设计与关键结果
- 系统评价与Meta分析,检索Medline、Embase、Cochrane、clinicaltrials.gov和WHO国际临床试验注册平台至2025年2月10日,纳入26项新RCT,评估20种注射治疗。
- 纳入RCT中12项为I级(低偏倚风险)、9项为II级、4项为III级。
- 高度可能有效(基于多项I级研究):丙氯拉嗪静脉注射、右酮洛芬静脉注射、舒马曲普坦皮下注射、枕大神经阻滞。
- 可能有效(基于一项I级或多项II级研究):氯丙嗪静脉注射、甲氧氯普胺静脉注射、依替奈珠单抗静脉注射、酮咯酸静脉注射、眶上神经阻滞。
- 可能无效(基于I级或多项II级研究):氢吗啡酮静脉注射、丙泊酚静脉注射、对乙酰氨基酚静脉注射。
证据类型、等级与局限
- 证据类型:指南更新,基于系统评价与Meta分析,采用AAN指南制定流程和AAN偏倚风险评估标准。
- 推荐等级照录原文:A级-必须提供、A级-必须不提供、B级-应提供、C级-可提供、C级-不应提供、U级-无推荐。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急诊成人偏头痛需胃肠外治疗且无禁忌时,丙氯拉嗪静脉注射或枕大神经阻滞为A级必须提供,改变了2016版以来的首选路径。
- 氢吗啡酮静脉注射为A级必须不提供,急诊不应以静脉阿片作为偏头痛相关疼痛的常规处理。
- 对乙酰氨基酚静脉注射为C级不应提供,不应作为偏头痛相关疼痛的常规静脉镇痛选择。
- 依替奈珠单抗仅对符合临床试验人群者应提供(B级),对急诊特定人群无推荐(U级),适用人群需按试验入组标准把握。
- 咖啡因、格拉司琼、布洛芬、氯胺酮、利多卡因、生理盐水、丙泊酚和蝶腭神经节阻滞目前均为U级-无推荐,作者认为需更多证据。
指南或共识出处
- 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies(美国头痛学会,2025年)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To update the 2016 American Headache Society (AHS) guideline on parenteral pharmacologic therapies for the management of migraine attacks in the emergency department (ED).
METHODS: We conducted a systematic review and meta-analysis using the same methodology as the 2016 guideline. The original search strategy was repeated and expanded to include studies of nerve blocks and sphenopalatine ganglion (SPG) blocks. We searched Medline, Embase, Cochrane, clinicaltrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform through February 10, 2025. Eligible studies were randomized controlled trials (RCTs) involving adults diagnosed with migraine, treated in the ED with intravenous (IV), intramuscular (IM), subcutaneous (SC), or nerve block (including SPG block) interventions. Two reviewers independently screened titles/abstracts and full texts; a third reviewer resolved disagreements. Data were extracted using a standardized form and verified by a second reviewer. Risk of bias was assessed using the American Academy of Neurology (AAN) criteria. Where applicable, meta-analyses were performed. Efficacy was categorized as highly likely, likely, or possibly effective or ineffective. Clinical recommendations were developed using the AAN guideline development process.
RESULTS: The search identified 26 new RCTs evaluating 20 injectable treatments. Of these, 12 were rated class I (low risk of bias), 9 class II, and 4 class III. Prochlorperazine IV, dexketoprofen IV, sumatriptan SC, and greater occipital nerve blocks (GONB) were considered highly likely to be effective based on multiple class I studies. Chlorpromazine IV, metoclopramide IV, eptinezumab IV, ketorolac IV, and supraorbital nerve blocks (SONB) were considered likely effective based on one class I or multiple class II studies. Hydromorphone IV, propofol IV, and paracetamol IV were considered likely ineffective based on class I or multiple class II studies. After review of the evidence and a consensus process, recommendations were made for each intervention.
CONCLUSIONS: Prochlorperazine IV and GONB must be offered to eligible adults presenting to the ED with a migraine attack for treatment of headache requiring parenteral therapy (level A - must offer) in those without contraindications, while hydromorphone IV must not be offered (level A - must not offer). Treatments that should be offered when appropriate (level B - should offer) include dexketoprofen IV, ketorolac IV, metoclopramide IV, sumatriptan SC, and SONB. Chlorpromazine IV, dexamethasone IV, and valproate IV may be offered (level C - may offer). Paracetamol IV may not be offered (level C - should not offer). Eptinezumab should be offered (level B) only for patients matching the clinical trial population but is rated level U - no recommendation for an ED-specific population. Additional evidence is needed for caffeine, granisetron, ibuprofen, ketamine, lidocaine, normal saline, propofol, and SPG blocks, all currently rated level U - no recommendation.
Migraine is a common cause of emergency department (ED) visits due to headache, but treatments offered in the ED can vary. This paper presents updated clinical practice guidelines for managing migraine attacks in the ED, which were informed by new clinical trial data evaluating treatments for migraine attacks in the ED and a rigorous review process. This updated review found that: (1) intravenous prochlorperazine and greater occipital nerve blocks had the strongest evidence and must be offered to patients in the ED; (2) several other treatments were found to be helpful and should be offered; and (3) intravenous opioids and intravenous paracetamol/acetaminophen are not recommended for migraine‐related pain relief.
参考来源
- Robblee J, Minen MT, Friedman BW, et al. 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2025. PMID: 41321235. doi:10.1111/head.70016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。